<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764293</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-III-310</org_study_id>
    <nct_id>NCT03764293</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC</brief_title>
  <official_title>A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, international, multi-center, phase III trial to evaluate
      the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line
      therapy in patients with advanced HCC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the overall survival (OS) of SHR-1210 plus apatinib with sorafenib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the progression-free survival (PFS) of SHR-1210 plus apatinib with sorafenib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the time to progression (TTP) of SHR-1210 plus apatinib with sorafenib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare objective response rate (ORR) of SHR-1210 plus apatinib with sorafenib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare disease control rate (DCR) of SHR-1210 plus apatinib with sorafenib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare duration of response (DoR) of SHR-1210 plus apatinib with sorafenib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) of SHR-1210 plus apatinib versus sorafenib as assessed by CTCAE v4.03</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of SHR-1210 and plasma concentration of apatinib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of anti-SHR-1210 antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate the time to deteriation (TTD) of SHR-1210 plus apatinib versus sorafenib</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Locally Advanced or Metastatic and Unresectable HCC</condition>
  <arm_group>
    <arm_group_label>SHR-1210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1210+Apatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial</description>
    <arm_group_label>SHR-1210</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet</description>
    <arm_group_label>SHR-1210</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically or cytologically confirmed advanced HCC

          -  No previous systematic treatment for HCC

          -  Have at least one measurable lesion (in accordance with RECIST v1.1)

          -  BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed
             following surgical and/or local therapy

          -  ECOG-PS score 0 or 1

          -  Child-Pugh Class: Grade A

          -  Life Expectancy of at least 12 weeks

          -  Subjects with HBV infection: HBV DNAï¼œ500 IU/ml or &lt; 2500 copy/mL, and have received
             anti-HBV therapy for at least 14 days prior to enrollment in the study

          -  Subjects with HCV-RNA(+) must receive antiviral therapy

          -  Adequate organ function

        Exclusion Criteria:

          -  Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar
             cell carcinoma; other active malignant tumor except HCC within 5 years or
             simultaneously

          -  Moderate-to-severe ascites with clinical symptoms

          -  History of gastrointestinal hemorrhage within 6 months prior to the start of study
             treatment or clear tendency of gastrointestinal hemorrhage

          -  Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6
             months prior to the start of study treatment

          -  Known genetic or acquired hemorrhage or thrombotic tendency

          -  Thrombosis or thromboembolic event within 6 months prior to the start of study
             treatment

          -  Cardiac clinical symptom or disease that is not well controlled

          -  Hypertension that can not be well controlled through antihypertensive drugs

          -  Factors to affect oral administration

          -  History of hepatic encephalopathy

          -  Previous or current presence of metastasis to central nervous system

          -  HIV infection

          -  Combined hepatitis B and hepatitis C co-infection

          -  Be ready for or previously received organ or allogenic bone marrow transplantation

          -  Interstitial lung disease that is symptomatic or may interfere with the detection and
             management of suspected drug-related pulmonary toxicity

          -  Active known, or suspected autoimmune disease

          -  Subjects with a condition requiring systemic treatment with either corticosteroids or
             other immunosuppressive medications within 14 days of first administration of study
             treatment

          -  Use of potent CYP3A4 inducers or inhibitors within 2 weeks prior to the signature of
             ICF

          -  Known history of serious allergy to any monoclonal antibody or targeted
             anti-angiogenic drug

          -  Severe infection within 4 weeks prior to the start of study treatment

          -  Palliative radiotherapy for non-target lesions to control symptoms is allowed, but it
             must be completed at least 2 weeks prior to the start of study treatment

          -  Treatment of other investigational product(s) within 28 days prior to the start of
             study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shukui Qin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 81st Hospital of People's Liberation Army</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linna Wang, MD</last_name>
    <phone>086-021-60453196</phone>
    <email>wanglinna@hrglobe.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincal Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yifu He</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Provincal Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weidong Jia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kangsheng Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhendong Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baocai Xing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunyi Hao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University International Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102206</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Liang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Affiliated To AMU</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Hao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital Affiliated To AMU</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houjie Liang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TheThird Affiliated Hospital ,Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of ChongQing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Ren</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 940th Hospital of the joint logistic support force of People's Liberation Army</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baihong Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510220</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajin Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NanFang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yabing Guo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of guangxi medical university</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Da Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxian Bai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital,Tongji Medical College,Huazhong University of Science&amp;Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji hospital,Tongji Medical College,Huazhong University of Science&amp;Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanzhi Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 81st Hospital of People's Liberation Army</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shukui Qin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianping Xiong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenyang 6th people's hospital</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <zip>110006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingdong Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqiang Meng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenggang Ren</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200043</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofeng zhai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital&amp;Institute</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongdong Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Da Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZheJiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieer Ying</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijia Fang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 28, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

